

DSU Addendum: 13/01/2009

Bevacizumab analyses

1. Original DSU Table 7

The following table replicates the cost-effectiveness estimates presented in the previous DSU report (28/08/08). These results were based on the PenTAG model using the parameter values suggested by Roche in relation to costings. Because of the issues in relation to the post hoc analyses, results were presented for different overall survival HRs.

It should be noted that in re-running the model, a minor error was noted in one of the original estimates. The ICER for Scenario 2 based on the final costing assumption (iii) should have been £69, 047 per QALY and not £73,146.

Table 7: Revised cost-effectiveness for bevacizumab using alternative costing assumptions

Costing Assumption	Base-Case <i>HR OS = 0.75</i> <i>HR PFS = 0.63</i>	Scenario 1 <i>HR OS = 0.613</i> <i>HR PFS = 0.63</i>	Scenario 2 <i>HR OS = 0.63</i> <i>HR PFS = 0.63</i>
<i>Bevacizumab – Base case costings</i>	£171,301	£101,340	£107,489
(i) Bevacizumab – Revised dosage only	£124,402	£74,008	£78,406
(ii) Bevacizumab – Revised dosage AND Revised number of administrations	£114,624	£68,561	£72,610
(iii) Bevacizumab – Revised dosage AND revised number of administrations AND revised unit cost of administration*	£108,835	£65,213	<u>£73,146 (£69,047)</u>

NB: Underlined ICER of £73,146 incorrect. Should be £69,047

* unit cost=£98 (compared to £197)

2. Revised DSU Table 7

As part of their commentary on the additional evidence used in the original DSU analysis, Roche provided alternative estimates affecting the costing assumptions applied in the original DSU analysis. Specifically, Roche identified an error in the methodology for calculating the expected mean dose and alternative estimates were provided. In addition, Roche applied an alternative estimate for the cost of administration of £170. The impact of applying these changes is reported below.

Costing Assumption	Base-Case <i>HR OS = 0.75</i> <i>HR PFS = 0.63</i>	Scenario 1 <i>HR OS = 0.613</i> <i>HR PFS = 0.63</i>	Scenario 2 <i>HR OS = 0.63</i> <i>HR PFS = 0.63</i>
<i>Bevacizumab – Base case costings</i>	£171,301	£101,340	£107,489
(i) Bevacizumab – Revised dosage only	£140,435	£83,489	£88,494
(ii) Bevacizumab – Revised dosage AND Revised number of administrations	£132,911	£79,138	£83,863
(iii) Bevacizumab – Revised dosage AND revised number of administrations AND revised unit cost of administration*	ICER £131,072	ICER £78,074	ICER £82,732

*Unit cost = £170 (compared to £197)